We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Promethean | LSE:PTH | London | Ordinary Share | GB00B08H5G38 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.125 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:0964K
PPL Therapeutics PLC
16 April 2003
For the attention of Company Announcements, London Stock Exchange
On Monday 28 April 2003, PPL Therapeutics plc, a leading company in the
application of transgenic technology to the production of human proteins for
therapeutic applications, will be announcing its preliminary results for the
year ended 31 December 2002.
An analyst briefing will be held at the offices of Hudson Sandler on Monday 28
April 2003, for further information please contact:
Alistair Mackinnon-Musson
Philip Dennis
Hudson Sandler
Tel: 020 7796 4133
e-mail: ppl@hspr.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORFGGMDLVDGFZG
1 Year Promethean Chart |
1 Month Promethean Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
